Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:1687–1717.
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.
)| false
GailMH, CostantinoJP, BryantJ et al.. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst1999;91:1829–1846.
GailMHCostantinoJPBryantJ. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829–1846.
)| false
GundryKR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park)2005;19:159–169; discussion 170, 173–154, 177.
GundryKR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159–169; discussion 170, 173–154, 177.
)| false
HoussamiN, CiattoS, MacaskillP et al.. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol2008;26:3248–3258.
HoussamiNCiattoSMacaskillP. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248–3258.
)| false
FischerU, ZachariaeO, BaumF et al.. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol2004;14:1725–1731.
FischerUZachariaeOBaumF. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:1725–1731.
)| false
SolinLJ, OrelSG, HwangWT et al.. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol2008;26:386–391.
SolinLJOrelSGHwangWT. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386–391.
)| false
Members of the Breast Cancer Disease Site Group. Program in evidence-based care: a Cancer Care Ontario Program. Baseline staging tests in primary breast cancer. Practice guideline report #1-14. April30, 2003. Available at: http://www.cancercare.on.ca/pdf/pebc1-14f.pdf. Accessed October 3, 2007.
Members of the Breast Cancer Disease Site Group. Program in evidence-based care: a Cancer Care Ontario Program. Baseline staging tests in primary breast cancer. Practice guideline report #1-14. April30, 2003. Available at: http://www.cancercare.on.ca/pdf/pebc1-14f.pdf. Accessed October 3, 2007.
)| false
PuglisiF, FolladorA, MinisiniAM et al.. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol2005;16:263–266.
PuglisiFFolladorAMinisiniAM. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263–266.
)| false
KumarR, ChauhanA, ZhuangH et al.. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat2006;98:267–274.
KumarRChauhanAZhuangH. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267–274.
)| false
WahlRL, SiegelBA, ColemanRE, GatsonisCG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol2004;22:277–285.
WahlRLSiegelBAColemanREGatsonisCG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277–285.
)| false
WangS, SaboorianMH, FrenkelE et al.. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol2000;53:374–381.
WangSSaboorianMHFrenkelE. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374–381.
)| false
AndersonS, GilkersonE, KleinP. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat2002;76:S68:Abstract 235.
AndersonSGilkersonEKleinP. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat 2002;76:S68:Abstract 235.
)| false
PaikS, BryantJ, Tan-ChiuE et al.. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst2002;94:852–854.
PaikSBryantJTan-ChiuE. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852–854.
)| false
PaikS, Tan-ChiuE, BryantJ et al.. Successful quality assurance program for HER2 testing in the NSABP trial for herceptin. Breast Cancer Res and Treat2002;76(Suppl):S31.
PaikSTan-ChiuEBryantJ. Successful quality assurance program for HER2 testing in the NSABP trial for herceptin. Breast Cancer Res and Treat 2002;76(Suppl):S31.
)| false
PerezEA, SumanVJ, DavidsonNE et al.. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol2006;24:3032–3038.
PerezEASumanVJDavidsonNE. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:3032–3038.
)| false
TubbsRR, PettayJD, RochePC et al.. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol2001;19:2714–2721.
TubbsRRPettayJDRochePC. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714–2721.
)| false
PressMF, SauterG, BernsteinL et al.. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res2005;11:6598–6607.
PressMFSauterGBernsteinL. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598–6607.
)| false
CarlsonRW, MoenchSJ, HammondMEH et al.. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw2006;4(Suppl 3):S1–22.
WolffAC, HammondME, SchwartzJN et al.. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol2007;25:118–147.
WolffACHammondMESchwartzJN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–147.
)| false
PaikS, BryantJ, ParkC et al.. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst1998;90:1361–1370.
PaikSBryantJParkC. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370.
)| false
PaikS, BryantJ, Tan-ChiuE et al.. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst2000;92:1991–1998.
PaikSBryantJTan-ChiuE. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991–1998.
)| false
PiccartMJ, Di LeoA, HamiltonA. HER2 a ‘predictive factor’ ready to use in the daily management of breast cancer patients?Eur J Cancer2000;36:1755–1761.
PiccartMJDi LeoAHamiltonA. HER2 a ‘predictive factor’ ready to use in the daily management of breast cancer patients?Eur J Cancer 2000;36:1755–1761.
)| false
ThorAD, BerryDA, BudmanDR et al.. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst1998;90:1346–1360.
ThorADBerryDABudmanDR. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.
)| false
DresslerLG, BerryDA, BroadwaterG et al.. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol2005;23:4287–4297.
DresslerLGBerryDABroadwaterG. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287–4297.
)| false
Piccart-GebhartMJ, ProcterM, Leyland-JonesB et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005;353:1659–1672.
Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.
)| false
SlamonD, EiermannW, RobertN et al.. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 52.
SlamonDEiermannWRobertN. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 52.
)| false
JoensuuH, Kellokumpu-LehtinenPL, BonoP et al.. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006;354:809–820.
JoensuuHKellokumpu-LehtinenPLBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820.
)| false
CobleighMA, VogelCL, TripathyD et al.. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol1999;17:2639–2648.
CobleighMAVogelCLTripathyD. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
)| false
SlamonDJ, Leyland-JonesB, ShakS et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001;344:783–792.
SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
)| false
VogelCL, CobleighMA, TripathyD et al.. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol2002;20:719–726.
VogelCLCobleighMATripathyD. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.
)| false
RhodesA, JasaniB, BarnesDM et al.. Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol2000;53:125–130.
RhodesAJasaniBBarnesDM. Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125–130.
)| false
RudigerT, HöflerH, KreipeHH et al.. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol2002;26:873–882.
RudigerTHöflerHKreipeHH. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873–882.
)| false
ArriagadaR, LeMG, RochardF, ContessoG. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol1996;14:1558–1564.
ArriagadaRLeMGRochardFContessoG. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:1558–1564.
)| false
ClarkeM, CollinsR, DarbyS et al.. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;366:2087–2106.
ClarkeMCollinsRDarbyS. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106.
)| false
FisherB, AndersonS, BryantJ et al.. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med2002;347:1233–1241.
FisherBAndersonSBryantJ. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233–1241.
)| false
VeronesiU, CascinelliN, MarianiL et al.. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med2002;347:1227–1232.
VeronesiUCascinelliNMarianiL. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227–1232.
)| false
McCormickB. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw2005;3:301–307.
McCormickB. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw 2005;3:301–307.
)| false
PignolJ-P, OlivottoE, RakovitchWE et al.. Phase III randomized study of intensity modulated radiation therapy vs. standard wedging adjuvant breast radiotherapy. Int J Rad Oncol2006;66:S1.
PignolJ-POlivottoERakovitchWE. Phase III randomized study of intensity modulated radiation therapy vs. standard wedging adjuvant breast radiotherapy. Int J Rad Oncol 2006;66:S1.
)| false
WhelanT, MacKenzieR, JulianJ et al.. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst2002;94:1143–1150.
WhelanTMacKenzieRJulianJ. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143–1150.
)| false
AntoniniN, JonesH, HoriotJC et al.. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol2007;82:265–271.
AntoniniNJonesHHoriotJC. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol 2007;82:265–271.
)| false
BartelinkH, HoriotJC, PoortmansP et al.. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med2001;345:1378–1387.
BartelinkHHoriotJCPoortmansP. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378–1387.
)| false
JonesH, AntoniniN, ColetteL et al.. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial [abstract]. Int J Radiat Oncol Biol Phys2007;69(3 Suppl):S2–3.
JonesHAntoniniNColetteL. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial [abstract]. Int J Radiat Oncol Biol Phys 2007;69(3 Suppl):S2–3.
)| false
FourquetA, CampanaF, ZafraniB et al.. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys1989;17:719–725.
FourquetACampanaFZafraniB. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719–725.
)| false
KomoikeY, AkiyamaF, IinoY et al.. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer2006;106:35–41.
KomoikeYAkiyamaFIinoY. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:35–41.
)| false
ZhouP, GautamS, RechtA. Factors affecting outcome for young women with early stage invasive cancer treated with breast-conserving therapy. Breast Cancer Res Treat2007;101:51–57.
ZhouPGautamSRechtA. Factors affecting outcome for young women with early stage invasive cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:51–57.
)| false
GolshanM, MironA, NixonAJ et al.. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg2006;192:58–62.
GolshanMMironANixonAJ. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192:58–62.
)| false
KromanN, HoltvegH, WohlfahrtJ et al.. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer2004;100:688–693.
KromanNHoltvegHWohlfahrtJ. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688–693.
)| false
HughesKS, SchnaperLA, BerryD et al.. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med2004;351:971–977.
HughesKSSchnaperLABerryD. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971–977.
)| false
HughesKS, SchnaperLA, BerryD et al.. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up. Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, Texas. Abstract 11.
HughesKSSchnaperLABerryD. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up. Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, Texas. Abstract 11.
)| false
FylesAW, McCreadyDR, ManchulLA et al.. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med2004;351:963–970.
FylesAWMcCreadyDRManchulLA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963–970.
)| false
RechtA, ComeSE, HendersonIC et al.. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med1996;334:1356–1361.
RechtAComeSEHendersonIC. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356–1361.
)| false
DubeyA, RechtA, ComeSE et al.. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys1999;45:877–884.
DubeyARechtAComeSE. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 1999;45:877–884.
)| false
MarkiewiczDA, SchultzDJ, HaasJA et al.. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys1996;35:661–668.
MarkiewiczDASchultzDJHaasJA. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 1996;35:661–668.
)| false
AbnerAL, RechtA, ViciniFA et al.. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys1991;21:331–338.
AbnerALRechtAViciniFA. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1991;21:331–338.
)| false
LymanGH, GiulianoAE, SomerfieldMR et al.. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol2005;23:7703–7720.
LymanGHGiulianoAESomerfieldMR. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703–7720.
)| false
O’HeaBJ, HillAD, El-ShirbinyAM et al.. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg1998;186:423–427.
O’HeaBJHillADEl-ShirbinyAM. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423–427.
)| false
VeronesiU, PaganelliG, VialeG et al.. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med2003;349:546–553.
VeronesiUPaganelliGVialeG. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546–553.
)| false
KuehnT, VoglFD, HelmsG et al.. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol2004;30:252–259.
KuehnTVoglFDHelmsG. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252–259.
)| false
ManselRE, FallowfieldL, KissinM et al.. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst2006;98:599–609.
ManselREFallowfieldLKissinM. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599–609.
)| false
CoxCE, SaludCJ, CantorA et al.. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg2001;193:593–600.
CoxCESaludCJCantorA. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593–600.
)| false
AxelssonCK, MouridsenHT, ZedelerK. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer1992;28A:1415–1418.
AxelssonCKMouridsenHTZedelerK. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415–1418.
)| false
KiricutaCI, TauschJ. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer1992;69:2496–2501.
KiricutaCITauschJ. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:2496–2501.
)| false
FisherB, RedmondC, FisherER et al.. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med1985;312:674–681.
FisherBRedmondCFisherER. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674–681.
)| false
FisherB, BryantJ, WolmarkN et al.. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol1998;16:2672–2685.
FisherBBryantJWolmarkN. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–2685.
)| false
BearHD, AndersonS, SmithRE et al.. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol2006;24:2019–2027.
BearHDAndersonSSmithRE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol 2006;24:2019–2027.
)| false
BuzdarAU, IbrahimNK, FrancisD et al.. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol2005;23:3676–3685.
BuzdarAUIbrahimNKFrancisD. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–3685.
)| false
SmithIE, DowsettM, EbbsSR et al.. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol2005;23:5108–5116.
SmithIEDowsettMEbbsSR. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108–5116.
)| false
EllisMJ, CoopA, SinghB et al.. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol2001;19:3808–3816.
EllisMJCoopASinghB. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–3816.
)| false
OvergaardM, JensenMB, OvergaardJ et al.. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet1999;353:1641–1648.
OvergaardMJensenMBOvergaardJ. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641–1648.
)| false
RagazJ, OlivottoIA, SpinelliJJ et al.. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst2005;97:116–126.
RagazJOlivottoIASpinelliJJ. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116–126.
)| false
OvergaardM, HansenPS, OvergaardJ et al.. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med1997;337:949–955.
OvergaardMHansenPSOvergaardJ. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949–955.
)| false
RechtA, EdgeSB, SolinLJ et al.. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol2001;19:1539–1569.
RechtAEdgeSBSolinLJ. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569.
)| false
TheriaultR, BuzdarA, HortobagyiG et al.. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—M.D. Anderson experience [abstract]. Proc Am Soc Clin Oncol1998;17:99a. Abstract 381.
TheriaultRBuzdarAHortobagyiG. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—M.D. Anderson experience [abstract]. Proc Am Soc Clin Oncol 1998;17:99a. Abstract 381.
)| false
McGuireSE, Gonzolez-AnguloAM, HuangEH et al.. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys2007;68:1004–1009.
McGuireSEGonzolez-AnguloAMHuangEH. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:1004–1009.
)| false
HuangEH, TuckerSL, StromEA et al.. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol2004;22:4691–4699.
HuangEHTuckerSLStromEA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691–4699.
)| false
OvergaardM, NielsenHM, OvergaardJ. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol2007;82:247–253.
OvergaardMNielsenHMOvergaardJ. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247–253.
)| false
NielsenHM, OvergaardM, GrauC et al.. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol2006;24:2268–2275.
NielsenHMOvergaardMGrauC. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268–2275.
)| false
AndersonBO, MasettiR, SilversteinMJ, Oncoplastic approaches to the partial mastectomy: an overview of volume displacement techniques. Lancet Oncol2005;6:145–157.
AndersonBOMasettiRSilversteinMJ, Oncoplastic approaches to the partial mastectomy: an overview of volume displacement techniques. Lancet Oncol 2005;6:145–157.
)| false
HuemerGM, SchrenkP, MoserF et al.. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg2007;120:390–398.
MalychaPL, GoughIR, MargaritoniM et al.. Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg2008;32:2570–2577.
MalychaPLGoughIRMargaritoniM. Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg 2008;32:2570–2577.
)| false
KaurN, PetitJY et al.. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol2005;12:539–545.
KaurNPetitJY. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539–545.
)| false
RavdinPM, SiminoffLA, DavisGJ et al.. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol2001;19:980–991.
RavdinPMSiminoffLADavisGJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980–991.
)| false
OlivottoIA, BajdikCD, RavdinPM et al.. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol2005;23:2716–2725.
OlivottoIABajdikCDRavdinPM. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716–2725.
)| false
LoprinziCL, RavdinPM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw2003;1:189–198.
LoprinziCLRavdinPM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw 2003;1:189–198.
)| false
SorlieT, PerouCM, TibshiraniR et al.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A2001;98:10869–10874.
SorlieTPerouCMTibshiraniR. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–10874.
)| false
PerouCM, JeffreySS, van de RijnM et al.. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A1999;96:9212–9217.
PerouCMJeffreySSvan de RijnM. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212–9217.
)| false
SorlieT, TibshiraniR, ParkerJ et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A2003;100:8418–8423.
SorlieTTibshiraniRParkerJ. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418–8423.
)| false
WangY, KlijnJG, ZhangY et al.. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet2005;365:671–679.
GlasAM, FlooreA, DelahayeLJ et al.. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics2006;7:278–287.
PaikS, TangG, ShakS et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol2006;24:3726–3734.
PaikSTangGShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.
)| false
SwainSM, WilsonJW, MamounasEP et al.. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst2004;96:516–523.
SwainSMWilsonJWMamounasEP. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516–523.
)| false
BerryD, CirrincioneC, HendersonIC et al.. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA2006;295:1658–1667.
BerryDCirrincioneCHendersonIC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.
)| false
AlbainK, BarlowW, O’MalleyF et al.. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 [meeting abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, Texas. Abstract LBA37.
AlbainKBarlowWO’MalleyF. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 [meeting abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, Texas. Abstract LBA37.
)| false
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–1467.
)| false
BerryDA, MussHB, ThorAD et al.. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol2000;18:3471–3479.
BerryDAMussHBThorAD. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471–3479.
)| false
Eppenberger-CastoriS, KuengW, BenzC et al.. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol2001;19:645–656.
Eppenberger-CastoriSKuengWBenzC. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645–656.
)| false
KnoopAS, BentzenSM, NielsenMM et al.. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol2001;19:3376–3384.
KnoopASBentzenSMNielsenMM. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376–3384.
)| false
De LaurentiisM, ArpinoG, MassarelliE et al.. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res2005;11:4741–4748.
De LaurentiisMArpinoGMassarelliE. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741–4748.
)| false
PaikS, ShakS, TangG et al.. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol2005;23:16(Suppl 1): Abstract 510.
PaikSShakSTangG. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol 2005;23:16(Suppl 1): Abstract 510.
)| false
ArpinoG, GreenSJ, AllredDC et al.. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res2004;10:5670–5676.
ArpinoGGreenSJAllredDC. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670–5676.
)| false
DowsettM, AllredC, KnoxJ et al.. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol2008;26:1059–1065.
DowsettMAllredCKnoxJ. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059–1065.
)| false
CoombesRC, KilburnLS, SnowdonCF et al.. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet2007;369:559–570.
CoombesRCKilburnLSSnowdonCF. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369:559–570.
)| false
KaufmannM, JonatW, HilfrichJ et al.. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol2007;25:2664–2670.
KaufmannMJonatWHilfrichJ. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007;25:2664–2670.
)| false
GossPE, IngleJN, MartinoS et al.. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst2005;97:1262–1271.
GossPEIngleJNMartinoS. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271.
)| false
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol2008;9:45–53.
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53.
)| false
ThurlimannB, KeshaviahA, CoatesAS et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:2747–2757.
ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.
)| false
BaumM, BudzarAU, CuzickJ et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:2131–2139.
BaumMBudzarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.
)| false
HowellA, CuzickJ, BaumM et al.. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet2005;365:60–62.
HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62.
)| false
DuffyS, JacksonTL, LansdownM et al.. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod2006;21:545–553.
DuffySJacksonTLLansdownM. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545–553.
)| false
FallowfieldL, CellaD, CuzickJ et al.. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol2004;22:4261–4271.
FallowfieldLCellaDCuzickJ. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261–4271.
)| false
EastellR, AdamsJE, ColemanRE et al.. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol2008;26:1051–1057.
EastellRAdamsJEColemanRE. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051–1057.
)| false
DowsettM, CuzickJ, HowellA, JacksonI. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer2001;85:317–324.
DowsettMCuzickJHowellAJacksonI. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317–324.
)| false
BuzdarAU, GuastallaJP, NabholtzJM et al.. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer2006;107:472–480.
BuzdarAUGuastallaJPNabholtzJM. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006;107:472–480.
)| false
MouridsenH, KeshaviahA, CoatesAS et al.. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. 2007; J Clin Oncol2007;25:5715–5722.
MouridsenHKeshaviahACoatesAS. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. 2007; J Clin Oncol 2007;25:5715–5722.
)| false
BoccardoF, RubagottiA, PuntoniM et al.. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol2005;23:5138–5147.
BoccardoFRubagottiAPuntoniM. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138–5147.
)| false
BoccardoF, RubagottiA, GuglielminiP et al.. Switching to anastrozole versus continued treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol2006;17(Suppl 7):vii10–14.
BoccardoFRubagottiAGuglielminiP. Switching to anastrozole versus continued treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):vii10–14.
)| false
CoombesRC, HallE, GibsonLJ et al.. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:1081–1092.
CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.
)| false
JakeszR, JonatW, GnantM et al.. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet2005;366:455–462.
JakeszRJonatWGnantM. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–462.
)| false
JonatW, GnantM, boccardoF et al.. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol2006;7:991–996.
JonatWGnantMboccardoF. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991–996.
)| false
GossPE, IngleJN, MartinoS et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:1793–1802.
GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.
)| false
GossPE, PE, IngleJN, PaterJL et al.. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol2008;26:1948–1955.
GossPEPEIngleJNPaterJL. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948–1955.
)| false
WhelanTJ, GossPE, IngleJN et al.. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol2005;23:6931–6940.
WhelanTJGossPEIngleJN. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931–6940.
)| false
PerezEA, JosseRG, PritchardKI et al.. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol2006;24:3629–3635.
PerezEAJosseRGPritchardKI. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–3635.
)| false
BravermanAS, SawhneyH, TendlerA et al.. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol2002;21:Abstract 164.
BravermanASSawhneyHTendlerA. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 164.
)| false
SmithIE, DowsettM, YapYS et al.. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol2006;24:2444–2447.
SmithIEDowsettMYapYS. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444–2447.
)| false
Early Breast Cancer Trialists’ Collaborative GroupPolychemotherapy for early breast cancer: an overview of the randomised trials. Lancet1998;352:930–942
Early Breast Cancer Trialists’ Collaborative GroupPolychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930–942)| false
WoodWC, BudmanDR, KorzunAH et al.. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med1994;330:1253–1259.
WoodWCBudmanDRKorzunAH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253–1259.
)| false
MenardS, ValagussaP, PilottiS et al.. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol2001;19:329–335.
MenardSValagussaPPilottiS. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329–335.
)| false
MussHB, ThorAD, BerryDA et al.. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med1994;330:1260–1266.
MussHBThorADBerryDA. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260–1266.
)| false
BangSM, HeoDS, LeeKH et al.. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer2000;89:2521–2526.
BangSMHeoDSLeeKH. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:2521–2526.
)| false
FisherB, AndersonS, Tan-ChiuE et al.. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol2001;19:931–942.
FisherBAndersonSTan-ChiuE. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931–942.
)| false
FisherB, BrownAM, DimitrovNV et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol1990;8:1483–1496.
FisherBBrownAMDimitrovNV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.
)| false
FisherB, AndersonS, WickerhamDL et al.. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol1997;15:1858–1869.
FisherBAndersonSWickerhamDL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858–1869.
)| false
HendersonIC, BerryDA, DemetriGD et al.. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol2003;21:976–983.
HendersonICBerryDADemetriGD. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.
)| false
MamounasEP, BryantJ, LemberskyB et al.. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol2005;23:3686–3696.
MamounasEPBryantJLemberskyB. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686–3696.
)| false
CitronML, BerryDA, CirrincioneC et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003;21:1431–1439.
CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.
)| false
LevineMN, PritchardKI, BramwellVH et al.. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol2005;23:5166–5170.
LevineMNPritchardKIBramwellVH. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166–5170.
)| false
French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol2001;19:602–611.
French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602–611.
)| false
PiccartMJ, Di LeoA, BeauduinM et al.. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol2001;19:3103–3110.
PiccartMJDi LeoABeauduinM. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103–3110.
)| false
RocheH, FumoleauP, SpielmannM et al.. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol2006;24:5664–5671.
RocheHFumoleauPSpielmannM. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24:5664–5671.
)| false
SparanoJA, WangM, MartinoS et al.. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.
SparanoJAWangMMartinoS. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.
)| false
JonesS, HolmesF, O’ShaughnesseyJ et al.. Extended follow-up and analysis of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 12.
JonesSHolmesFO’ShaughnesseyJ. Extended follow-up and analysis of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 12.
)| false
PerezEA, RomondEH, SumanVJ et al.. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 512.
PerezEARomondEHSumanVJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 512.
)| false
Tan-ChiuE, YothersG, RomondE et al.. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol2005;23:7811–7819.
Tan-ChiuEYothersGRomondE. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–7819.
)| false
PerezEA, SumanVJ, DavidsonNE et al.. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North American Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol2008;26:1231–1238.
PerezEASumanVJDavidsonNE. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North American Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231–1238.
)| false
GeyerCE, BryantJL, RomondMS et al.. Update of cardiac dysfunction on NSABP-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol2006;24(Suppl 1):Abstract 581.
GeyerCEBryantJLRomondMS. Update of cardiac dysfunction on NSABP-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol 2006;24(Suppl 1):Abstract 581.
)| false
SmithI, ProcterM, GelberRD et al.. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet2007:369:29–36.
SmithIProcterMGelberRD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007:369:29–36.
)| false
NorrisB, ChiaS, CheangM et al.. Poor 10 yr breast cancer specific survival and relapse free survival for HER2-positive T1pN0 tumors. San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 2031.
NorrisBChiaSCheangM. Poor 10 yr breast cancer specific survival and relapse free survival for HER2-positive T1pN0 tumors. San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 2031.
)| false
UntchM, GelberRD, JackischC et al.. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol2008;19:1090–1096.
UntchMGelberRDJackischC. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090–1096.
)| false
Rosselli Del TurcoM, PalliD, CariddiA et al.. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-Up. JAMA1994;271:1593–1597.
Rosselli Del TurcoMPalliDCariddiA. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-Up. JAMA 1994;271:1593–1597.
)| false
SmithTJ, DavidsonNE, SchapiraDV et al.. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol1999;17:1080–1082.
SmithTJDavidsonNESchapiraDV. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:1080–1082.
)| false
The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA1994;271:1587–1592.
The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:1587–1592.
)| false
BastRCJr, RavdinP, HayesDF et al.. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol2001;19:1865–1878.
BastRCJrRavdinPHayesDF. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–1878.
)| false
KirovaYM, Stoppa-LyonnetD, SavignoniA et al.. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer2005;41:2304–2311.
KirovaYMStoppa-LyonnetDSavignoniA. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304–2311.
)| false
PierceLJ, LevinAM, RebbeckTR et al.. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol2006;24:2437–2443.
PierceLJLevinAMRebbeckTR. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437–2443.
)| false
American College of Obstetrics and Gynecology Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol2006;107:1475–1478.
American College of Obstetrics and Gynecology Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475–1478.
)| false
LoprinziCL, KuglerJW, SloanJA et al.. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet2000;356:2059–2063.
LoprinziCLKuglerJWSloanJA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–2063.
)| false
JinY, DestaZ, StearnsV et al.. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:30–39.
JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–39.
)| false
HillnerBE, IngleJN, ChlebowskiRT et al.. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:4042–4057.
HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.
)| false
EubankWB, MankoffD, BhattacharyaM et al.. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol2004;183:479–486.
EubankWBMankoffDBhattacharyaM. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479–486.
)| false
MoonDH, MaddahiJ, SilvermanDH et al.. Accuracy of whole-body fluorine-18-FDG PRT for the detection of recurrent or metastatic breast carcinoma. J Nucl Med1998;39:431–435.
MoonDHMaddahiJSilvermanDH. Accuracy of whole-body fluorine-18-FDG PRT for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431–435.
)| false
VernonCC, HandJW, FieldSB et al.. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys1996;35:731–744.
VernonCCHandJWFieldSB. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731–744.
)| false
ContePF, LatreilleJ, MauriacL et al.. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol.1996;14:2552–2559.
ContePFLatreilleJMauriacL. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552–2559.
)| false
HortobagyiGN, TheriaultRL, LiptonA et al.. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol1998;16:2038–2044.
HortobagyiGNTheriaultRLLiptonA. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038–2044.
)| false
TheriaultRL, LiptonA, HortobagyiGN et al.. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol1999;17:846–854.
TheriaultRLLiptonAHortobagyiGN. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846–854.
)| false
RosenLS, GordonD, KaminskiM et al.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377–387.
RosenLSGordonDKaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.
)| false
RosenLS, GordonDH, DuganWJr et al.. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100:36–43.
RosenLSGordonDHDuganWJr. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36–43.
)| false
LiptonA, TheriaultRL, HortobagyiGN et al.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:1082–1090.
LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
)| false
HortobagyiGN, TheriaultRL, PorterL et al.. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med1996;335:1785–1971.
HortobagyiGNTheriaultRLPorterL. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785–1971.
)| false
DielIJ, BodyJJ, LichinitserMR et al.. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer2004;40:1704–1712.
DielIJBodyJJLichinitserMR. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704–1712.
)| false
McLachlanSA, CameronD, MurrayR et al.. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig2006;26:43–48.
McLachlanSACameronDMurrayR. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:43–48.
)| false
PecherstorferM, RivkinS, BodyJJ et al.. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig2006;26:315–322.
PecherstorferMRivkinSBodyJJ. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315–322.
)| false
LiptonA, TheriaultRL, HortobagyiGN et al.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:1082–1090.
LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
)| false
RosenLS, GordonD, KaminskiM et al.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer2003;98:1735–1744.
RosenLSGordonDKaminskiM. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–1744.
)| false
WilkinsonGS, KuoYF, FreemanJL, GoodwinJS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst2007;99:1016–1024.
WilkinsonGSKuoYFFreemanJLGoodwinJS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016–1024.
)| false
WooSB, HellsteinJW, KalmarJR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Systematic Review Bisphosphonates Osteonecrosis of the Jaw. Ann Intern Med2006;144:753–761.
WooSBHellsteinJWKalmarJR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Systematic Review Bisphosphonates Osteonecrosis of the Jaw. Ann Intern Med 2006;144:753–761.
)| false
BuzdarA, DoumaJ, DavidsonN et al.. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol2001;19:3357–3366.
BuzdarADoumaJDavidsonN. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357–3366.
)| false
BuzdarAU, JonatW, HowellA et al.. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer1998;83:1142–1152.
BuzdarAUJonatWHowellA. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142–1152.
)| false
BonneterreJ, ThurlimannB, RobertsonJF et al.. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol2000;18:3748–3757.
BonneterreJThurlimannBRobertsonJF. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748–3757.
)| false
NabholtzJM, BuzdarA, PollakM et al.. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol2000;18:3758–3767.
NabholtzJMBuzdarAPollakM. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–3767.
)| false
VergoteI, BonneterreJ, ThurlimannB et al.. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer2000;36(Suppl 4):S84–85.
VergoteIBonneterreJThurlimannB. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000;36(Suppl 4):S84–85.
)| false
ParidaensR, TherasseP, DirixL et al.. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC Breast Group [abstract]. J Clin Oncol2004;22:14S (Suppl 1):Abstract 515.
ParidaensRTherassePDirixL. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC Breast Group [abstract]. J Clin Oncol 2004;22:14S (Suppl 1):Abstract 515.
)| false
KlijnJG, BlameyRW, BoccardoF et al.. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol2001;19:343–353.
KlijnJGBlameyRWBoccardoF. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343–353.
)| false
OsborneCK, PippenJ, JonesSE et al.. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol2002;20:3386–3395.
OsborneCKPippenJJonesSE. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386–3395.
)| false
HowellA, RobertsonJF, Quaresma AlbanoJ et al.. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol2002;20:3396–3403.
HowellARobertsonJFQuaresma AlbanoJ. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396–3403.
)| false
RobertsonJF, OsborneCK, HowellA et al.. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer2003;98:229–238.
RobertsonJFOsborneCKHowellA. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229–238.
)| false
IngleJN, SumanVJ, RowlandKM et al.. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol2006;24:1052–1056.
IngleJNSumanVJRowlandKM. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:1052–1056.
)| false
ChiaS, GradisharW, MauriacL et al.. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol2008;26:1664–1670.
ChiaSGradisharWMauriacL. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664–1670.
)| false
LonningPE, BajettaE, MurrayR et al.. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol2000;18:2234–2244.
LonningPEBajettaEMurrayR. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234–2244.
)| false
DombernowskyP, SmithI, FalksonG et al.. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol1998;16:453–461.
DombernowskyPSmithIFalksonG. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453–461.
)| false
BuzdarA, JonatW, HowellA et al.. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol1996;14:2000–2011.
BuzdarAJonatWHowellA. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000–2011.
)| false
CarrickS, ParkerS, WilckenN et al.. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev2005;2:CD003372.
CarrickSParkerSWilckenN. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;2:CD003372.
)| false
SledgeGW, NeubergD, BernardoP et al.. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol2003;21:588–592.
SledgeGWNeubergDBernardoP. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588–592.
)| false
O’ShaughnessyJ, MilesD, VukeljaS et al.. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol2002;20:2812–2823.
O’ShaughnessyJMilesDVukeljaS. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812–2823.
)| false
AlbainK, NagS, Calderillo-RuizJ et al.. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer. (MBC): First report of overall survival [abstract]. J Clin Oncol2004;22:14s(Suppl 1):Abstract 510.
AlbainKNagSCalderillo-RuizJ. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer. (MBC): First report of overall survival [abstract]. J Clin Oncol 2004;22:14s(Suppl 1):Abstract 510.
)| false
MussHB, CaseLD, RichardsFII et al.. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med1991:325;1342–1348.
MussHBCaseLDRichardsFII. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991:325;1342–1348.
)| false
FalksonG, GelmanR, PandyaK et al.. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol1998;16:1669–1676.
FalksonGGelmanRPandyaK. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:1669–1676.
)| false
RocheH, YelleL, CognettiF et al.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol2007;25:3415–3420.
RocheHYelleLCognettiF. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415–3420.
)| false
ThomasE, TaberneroJ, FornierM et al.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol2007;25:3399–3406.
ThomasETaberneroJFornierM. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399–3406.
)| false
PerezEA, LerzoG, PivotX et al.. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol2007;25:3407–3414.
PerezEALerzoGPivotX. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407–3414.
)| false
ThomasES, GomezHL, LiRK et al.. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol2007;25:5210–5217.
ThomasESGomezHLLiRK. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210–5217.
)| false
SeidmanAD, BerryD, CirrincioneC et al.. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Groups B protocol 9840. J Clin Oncol2008;26:1642–1649.
SeidmanADBerryDCirrincioneC. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Groups B protocol 9840. J Clin Oncol 2008;26:1642–1649.
)| false
RochePC, SumanVJ, JenkinsRB et al.. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst2002;94:855–857.
RochePCSumanVJJenkinsRB. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst 2002;94:855–857.
)| false
RobertN, Leyland-JonesB, AsmarK et al.. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol2006;24:2786–2792.
RobertNLeyland-JonesBAsmarK. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786–2792.
)| false
BursteinHJ, KeshaviahA, BaronAD et al.. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer2007;110:965–972.
BursteinHJKeshaviahABaronAD. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965–972.
)| false
YamamotoD, IwaseS, KitamuraK et al.. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network 00 trial. Cancer Chemother Pharmacol2008;61:509–514.
YamamotoDIwaseSKitamuraK. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network 00 trial. Cancer Chemother Pharmacol 2008;61:509–514.
)| false
SchallerG, BangemannN, WeberJ et al.. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. J Clin Oncol2005;23:18(Suppl 1):Abstract 717.
SchallerGBangemannNWeberJ. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. J Clin Oncol 2005;23:18(Suppl 1):Abstract 717.
)| false
Von MinckwitzG, VogelP, SchmidtM et al.. Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer—interim report [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4056.
Von MinckwitzG, ZielinskiC, MaarteenseE et al.. Capecitabine vs. Capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 1025.
Von MinckwitzGZielinskiCMaarteenseE. Capecitabine vs. Capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1025.
)| false
O’ShaughnessyJ, BlackwellKL, BursteinH et al.. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 1015.
O’ShaughnessyJBlackwellKLBursteinH. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1015.
)| false
BabieraGV, RaoR, FengL et al.. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol2006;13:776–782.
BabieraGVRaoRFengL. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776–782.
)| false
RapitiE, VerkooijenHM, VlastosG et al.. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol2006;24:2743–2749.
RapitiEVerkooijenHMVlastosG. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743–2749.
)| false
RaoR, FengL, KuererHM et al.. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol2008;15:1696–1702.
RaoRFengLKuererHM. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008;15:1696–1702.
)| false
MorrowM, GoldsteinLJ. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?J Clin Oncol2006;24:2694–2696.
MorrowMGoldsteinLJ. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?J Clin Oncol 2006;24:2694–2696.
)| false
OlsonJA, MarcomPK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg2008;247:739–740.
OlsonJAMarcomPK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg 2008;247:739–740.
)| false
ParadisoA, TommasiS, BrandiM et al.. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer1989;1:1922–1927.
ParadisoATommasiSBrandiM. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;1:1922–1927.
)| false
TurpinE, BiècheI, BertheauP et al.. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene2002;21:7593–7597.
TurpinEBiècheIBertheauP. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593–7597.
)| false
CristofanilliM, ValeroV, BuzdarAU et al.. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer2007;110.1436–1444.
CristofanilliMValeroVBuzdarAU. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 2007;110.1436–1444.
)| false
PanadesM, OlivottoIA, SpeersCH et al.. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol23:1941–1950.
MerajverSD, WeberBL, CodyR et al.. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience. J Clin Oncol1997;15:2873–2881.
MerajverSDWeberBLCodyR. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience. J Clin Oncol 1997;15:2873–2881.
)| false
HanceKW, AndersonWF, DevesaSS et al.. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Instit2005;97:966–975.
HanceKWAndersonWFDevesaSS. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Instit 2005;97:966–975.
)| false
NguyenDM, SamK, TsimelzonA et al.. Molecular heterogeneity of inflammatory breast cancer; a hyperproliferative phenotype. Clin Cancer Res2006;12:5047–5054.
NguyenDMSamKTsimelzonA. Molecular heterogeneity of inflammatory breast cancer; a hyperproliferative phenotype. Clin Cancer Res 2006;12:5047–5054.
)| false
BleicherRJ, MorrowM. What progress have we made in managing inflammatory breast cancer? The Dawood/Cristofanilli article reviewed. Oncology2007;21:679–680.
BleicherRJMorrowM. What progress have we made in managing inflammatory breast cancer? The Dawood/Cristofanilli article reviewed. Oncology 2007;21:679–680.
)| false
FlemingRY, AsmarL, BuzdarAU et al.. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast cancer. Ann Surg Oncol1997;4:452–461.
FlemingRYAsmarLBuzdarAU. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast cancer. Ann Surg Oncol 1997;4:452–461.
)| false
UenoNT, BuzdarAU, SingletarySE et al.. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol1997;40:321–324.
UenoNTBuzdarAUSingletarySE. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321–324.
)| false
TherasseP, MauriacL, Welnicka-JaskiewiczM et al.. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK Multicenter Study. J Clin Oncol2003;21:843–850.
TherassePMauriacLWelnicka-JaskiewiczM. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK Multicenter Study. J Clin Oncol 2003;21:843–850.
)| false
CristofanilliM, Gonzalez-AnguloAM, BuzdarAU et al.. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer2004;4:415–419.
CristofanilliMGonzalez-AnguloAMBuzdarAU. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 2004;4:415–419.
)| false
KimT, LauJ, ErbanJ. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer2006;7:386–395.
KimTLauJErbanJ. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer 2006;7:386–395.
)| false
BlanchardDK, ShettyPB, HilsenbeckSG, ElledgeRM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg2008;247:732–738.
BlanchardDKShettyPBHilsenbeckSGElledgeRM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008;247:732–738.
)| false
OlsonJA, MorrisEA, Van ZeeKJ et al.. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol2000;7:411–415.
